NCT03399773View on ClinicalTrials.gov

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

June 9, 2025

Study Completion Date

April 2, 2027

Conditions
Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts
Interventions
BIOLOGICAL

Dilanubicel

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Thiotepa

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Umbilical Cord Blood Transplantation

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspirate

Undergo bone marrow aspirate and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspirate and biopsy

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Electrocardiography

Undergo ECHO

PROCEDURE

Computed Tomography

Undergo CT

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Nohla Therapeutics, Inc.
All Listed Sponsors
collaborator

Nohla Therapeutics, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER